Sex steroids and prostate carcinogenesis: Integrated, multifactorial working hypothesis

Annals of the New York Academy of Sciences

Volumn 1089, Issue , 2006, Pages 168-176

  Bosland, Maarten C ^a,b,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Carcinogenesis; Estrogen, androgen; Hormonal carcinogenesis; Prostate; Prostate cancer

Indexed keywords

ANDROGEN; ANDROSTANOLONE; AROMATASE; BROMOCRIPTINE; CARCINOGEN; CATECHOL ESTROGEN; DNA; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; REACTIVE OXYGEN METABOLITE; SEX HORMONE; TAMOXIFEN; TESTOSTERONE;

AGING; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CONFERENCE PAPER; DNA DAMAGE; ENVIRONMENTAL FACTOR; GENOTOXICITY; HUMAN; HYPOTHESIS; INFLAMMATION; METABOLITE; NONHUMAN; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; RISK FACTOR; TREATMENT DURATION; ANIMAL; ARTICLE; CELL TRANSFORMATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; RAT;

ANIMALIA; RATTUS; RODENTIA;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; GONADAL STEROID HORMONES; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RATS; RECEPTORS, ESTROGEN;

EID: 33847779665     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1386.040     Document Type: Conference Paper

References (33)

1. BOSLAND, M.C. 2000. The role of steroid hormones in prostate carcinogenesis. J. Natl. Cancer Inst. Monogr. 27: 39-66.
2. CHAN, J.M., P.H. GANN & E.L. GIOVANNUCCI. 2005. Role of diet in prostate cancer development and progression. J. Clin. Oncol. 23: 8152-8160.
3. GANN, P.H. 2002. Risk factors for prostate cancer. Rev. Urol. 4(Suppl 5): S3-S10.
4. PLATZ, E.A. & E. GIOVANNUCCI. 2004. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J. Steroid Biochem. Mol. Biol. 92: 237-253.
5. PALAPATTU, G.S., S. SUTCLIFFE, P.J. BASTIAN, et al. 2005. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 26: 1170-1181.
6. MORGENTALER, A. 2006. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur. Urol. 50: 935-939. Jul 27 [Epub ahead of print].
7. EATON, N.E., G.K. REEVES, P.N. APPLEBY & T.J. KEY. 1999. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br. J. Cancer 80: 930-934.
8. GANN, P.H., C.H. HENNEKENS, J. MA, et al. 1996. Prospective study of sex hormone levels and risk of prostate cancer. J. Natl. Cancer Inst. 88: 1118-1126.
9. SEVERI, G., H.A. MORRIS, R.J. MACI NNIS, et al. 2006. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 15: 86-91.
10. TAPLIN, M.E. & S.P. BALK. 2004. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J. Cell. Biochem. 91: 483-490.
11. THOMPSON, I.M., P.J. GOODMAN, C.M. TANGEN, et al. 2003. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349: 215-224.
12. BOSLAND, M.C., H.C. DREEF-VAN DER MEULEN, S. SUKUMAR, et al. 1992. Multistage prostate carcinogenesis: the role of hormones. In Multistage Carcinogenesis. Proceedings of the 22nd International symposium of the Princess Takamatsu Cancer Research Fund. C.C. Harris, S. Hirohashi, N. Ito, H.C. Pitot, T. Sugimura, M. Terada, J. Yokota, Eds.: 109-123. Japan Sci. Soc. Press/Boca Raton, FL. CRC Press. Tokyo, Japan.
13. ELLEM, S.J., J.F. SCHMITT, J.S. PEDERSEN, et al. 2004. Local aromatase expression in human prostate is altered in malignancy. J. Clin. Endocrinol. Metab. 89: 2434-2441.
14. FOWLER, K.A., K. GILL, N. KIRMA, et al. 2000. Overexpression of aromatase leads to development of testicular leydig cell tumors: an in vivo model for hormone-mediated testicular cancer. Am. J. Pathol. 156: 347-353.
15. LI, X., E. NOKKALA, W. YAN, et al. 2001. Altered structure and function of reproductive organs in transgenic male mice overexpressing human aromatase. Endocrinology 142: 2435-2442.
16. MCPHERSON, S.J., H. WANG, M.E. JONES, et al. 2001. Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 142: 2458-2467.
17. BOSLAND, M.C., H. FORD & L. HORTON. 1995. Induction of a high incidence of ductal prostate adenocarcinomas in NBL and Sprague Dawley rats treated with estradiol-17β or diethylstilbestrol in combination with testosterone. Carcinogenesis 16: 1311-1317.
18. BOSLAND, M.C., H. FORD, L. HORTON, et al. 1995. Progression of putative precursor lesions of rat prostatic adenocarcinomas induced by estradiol-17β and androgens. Proc. Am. Assoc. Cancer Res. 36: 271.
19. LATIL, A., I. BIECHE, D. VIDAUD, et al. 2001. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 61: 1919-1926.
20. LAU, K.M., I. LEAV & S.M. HO. 1998. Rat estrogen receptor-alpha and -beta, and progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Noble rat. Endocrinology 139: 424-427.
21. LEAV, I., K.M. LAU, J.Y. ADAMS, et al. 2001. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 59: 79-92.
22. THOMPSON, C.J., N.N. TAM, J.M. JOYCE, et al. 2002. Gene expression profiling of testosterone and estradiol-17 beta-induced prostatic dysplasia in Noble rats and response to the antiestrogen ICI 182,780. Endocrinology 143: 2093-2105.
23. MCCORMICK, D.L., W.D. JOHNSON, R.A. LUBET, et al. 2002. Differential chemopreventive activity of the antiandrogen, flutamide, and the antiestrogen, tamoxifen, in the rat prostate [abstract 3178]. Proc. Am. Assoc. Cancer Res.
24. TANGBANLUEKAL, L. & C.L. ROBINETTE. 1993. Prolactin mediates estradiol-induced inflammation in the lateral prostate of Wistar rats. Endocrinology 132: 2407-2416.
25. LANE, K.E., I. LEAV, J. ZIAR, et al. 1997. Suppression of testosterone and estradiol-17beta-induced dysplasia in the dorsolateral prostate of Noble rats by bromocriptine. Carcinogenesis 18: 1505-1510.
26. CAVALIERI, E.L., P.D. DEVANESAN, M.C. BOSLAND, et al. 2002. Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer. Carcinogenesis 23: 329-333.
27. CAVALIERI, E., K. FRENKEL, J.G. LIEHR, et al. 2000. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J. Natl. Cancer Inst. Monogr. 27: 75-93.
28. CAVALIERI, E., D. CHAKRAVARTI, J. GUTTENPLAN, et al. 2006. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim. Biophys. Acta 1766: 63-78.
29. MAILANDER, P.C., J.L. MEZA, S. HIGGINBOTHAM & D. CHAKRAVARTI. 2006. Induction of A.T to G.C mutations by erroneous repair of depurinated DNA following estrogen treatment of the mammary gland of ACI rats. J. Steroid Biochem. Mol. Biol. 101: 204-215. Sep 16 [Epub ahead of print].
30. LIEHR, J.G. 2000. Role of DNA adducts in hormonal carcinogenesis. Regul. Toxicol. Pharmacol. 32: 276-282.
31. 32P-postlabeling in the dorsolateral prostate of NBL/Cr rats treated with estradiol-17β and testosterone. Carcinogenesis 16: 951-954.
32. VERMEULEN, A., J.M. KAUFMAN, S. GOEMAERE & I. VAN POTTELBERG. 2002. Estradiol in elderly men. Aging Male 5: 98-102.
33. ROSS, R.K., L. BERNSTEIN, R.A. LOBO, et al. 1992. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339: 887-889.